par Baleine, Manon;Haddad, Charbel 
;Zein El Din, A.;Van Bol, Laure ;Motulsky, Elie
Référence Revue médicale de Bruxelles, 45, 3, page (196-200)
Publication Publié, 2024-05-01
;Zein El Din, A.;Van Bol, Laure ;Motulsky, Elie Référence Revue médicale de Bruxelles, 45, 3, page (196-200)
Publication Publié, 2024-05-01
Article révisé par les pairs
| Résumé : | This review article examines the efficacy of faricimab, a bispecific antibody that inhibits both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2), in the treatment of age-related macular degeneration (AMD) and diabetic macular edema (DME). Both conditions can lead to blindness. AMD is characterized by the formation of choroidal neovascularization, while DME results from fluid accumulation in the macular region due to an alteration of the blood-retinal barrier. Clinical trials, including phase II studies (AVENUE, STAIRWAY) and phase III studies (TENAYA, LUCERNE) for AMD, as well as the BOULEVARD study for DME, demonstrate the non-inferiority of faricimab compared to current evidence-based treatments and a capacity to extend injection intervals. Real-world studies, such as TRUCKEE, confirm improvements in visual acuity and reduction in intra- or subretinal fluid with the use of faricimab. These promising results suggest that faricimab could be an effective alternative for patients resistant to current treatments. |
